CAS 1816989-16-8

Mevociclib

CAS : 1816989-16-8

Mevociclib

Degré de pureté : ≥98%

Masse moléculaire : 587.11g/mol

Ref: 54-BUP21837

N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide

Produit contrôlé

CAS : 1816989-16-8

Formule : C₃₁H₃₅ClN₈O₂

Couleur et forme : Neat

Masse moléculaire : 587.115

Ref: TR-C293035

Mevociclib

CAS : 1816989-16-8

Mevociclib is a potent inhibitor of the Bcl-2 protein, which is considered to be a key regulator of cell death. It binds to the kinase domain of the Bcl-2 protein, inhibiting its function and promoting apoptosis. Mevociclib has shown potent antitumor activity in clinical studies against patients with high-risk diseases such as cancer and cell culture experiments against carcinoma cells. This drug also inhibits transcriptional regulation by suppressing specific genes that inhibit apoptosis pathways.

Formule : C₃₁H₃₅ClN₈O₂

Degré de pureté : Min. 95%

Masse moléculaire : 587.11 g/mol

Ref: 3D-RXC98916

Mevociclib

CAS : 1816989-16-8

Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.

Formule : C₃₁H₃₅ClN₈O₂

Degré de pureté : 98.02% - 98.02%

Couleur et forme : Solid

Masse moléculaire : 587.11

Ref: TM-T13044